imarily 15198639” in vascular endothelial cells as well as epithelial and smooth muscle cells throughout the body. Early clinical manifestations of the disease include angiokeratoma, acroparesthesias, episodic pain “crises”, hypohydrosis, and gastrointestinal complaints. Progressive GL-3 accumulation in the microvasculature and parenchyma leads to microvascular dysfunction, occlusion, and ischemia. Recent reports 19464323” have described increased inflammation, oxidative stress, and circulating myeloperoxidase which appears to be associated with vasculopathic events. In adult males with Fabry disease, the renal, cardiovascular and cerebrovascular manifestations such as proteinuria, chronic kidney disease and kidney failure, cardiac arrhythmias, hypertrophic cardiomyopathy and strokes lead to early death during the fourth and fifth decade of life. A late onset cardiac variant has been described in male patients which is associated with progressive cardiac fibrosis and ultimate death in the 6th decade of life from the cardiac disease with preserved renal function. Recent studies have emphasized the importance of controlling proteinuria with inhibitors of the renin-angiotensin-aldosterone system in patients receiving enzyme 
replacement therapy 1 Cardiomyopathy in Fabry Mouse Model but even with stabilization of kidney function, some of these patients still experience cardiac events, including bradyarrhythmias, ventricular premature contractions and sustained ventricular arrhythmias and conduction delays as have been described in untreated patients. The cardiac manifestations in adults with Fabry disease, with emphasis on the non-obstructive, concentric hypertrophic cardiomyopathy are well described. Kampmann et al. have studied a large number of adolescents with Fabry disease; some present with early symptoms and signs of cardiac involvement, findings that have been confirmed by reports from Fabry registries. Mouse knock-out models for Fabry disease have been described. Shayman et al. have studied large vessel reactivity and pathology in this model. Recent work by Rozenfeld et al has described myocardial alterations in this model, and the response to ERT given at biweekly intervals for 2 months. In the present study, we found that Fabry KO male mice have bradycardia, low ABT-578 price systemic blood pressure and mild hypertrophic cardiomyopathy when compared to the control wildtype C57BL/6J mice. Molecular studies are consistent with early cardiac remodelling, and these changes were reversed rapidly in response to a single dose of ERT. end of high-amplitude electrical events, as detected on the first derivative. The QT interval was measured from the onset of the Q wave to the last detectable electrical event on the first derivative. QT interval was corrected for heart rate by drawing the linear regression line from individual beats for each mouse, and was expressed as the value at a RR of 150 msec. Echocardiography was performed on lightly anesthetized mice, as described previously. A small number of animals appeared to have more severe bradycardia in response anesthesia, and these animals were not included in the analysis of the echocardiograhy results to avoid non-specific rate-related changes. Briefly, the heart was visualized in the long axis parasternal view for M-mode left ventricle dimension measurement and posterior wall pulse wave tissue Doppler measurement. An apical 4- to 5-chamber view was obtained from the subcostal view for diastolic function assessment with